Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.


Journal

Oncology (Williston Park, N.Y.)
ISSN: 0890-9091
Titre abrégé: Oncology (Williston Park)
Pays: United States
ID NLM: 8712059

Informations de publication

Date de publication:
13 May 2020
Historique:
entrez: 10 7 2020
pubmed: 10 7 2020
medline: 20 8 2021
Statut: ppublish

Résumé

Triple-negative breast cancer (TNBC), which accounts for approximately 10% to 15% of breast cancers, remains the most aggressive subtype and is characterized by early disease relapse for a subset of patients. TNBC remains a clinical challenge, given the lack of effective targeted treatments such as endocrine therapy for hormone receptor-positive (HR+) tumors or therapies against HER2.

Identifiants

pubmed: 32644178

Substances chimiques

Biomarkers, Tumor 0
Poly(ADP-ribose) Polymerase Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-182

Auteurs

Andrew A Davis (AA)

Robert H. Lurie Comprehensive Cancer Center, Feingberg School of Medicine, Northwestern University, Chicago, IL.

William J Gradishar (WJ)

Robert H. Lurie Comprehensive Cancer Center, Feingberg School of Medicine, Northwestern University, Chicago, IL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH